# INO-VATE (NCT01564784)

> A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

No report yet. It can be ordered.

- Drugs tested: inotuzumab ozogamicin
- Indication: relapsed or refractory CD22-positive acute lymphoblastic leukemia

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01564784
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Pfizer
- Conditions: Acute Lymphoblastic Leukemia
- Interventions: inotuzumab ozogamicin; FLAG (fludarabine, cytarabine and G-CSF); HIDAC (high dose cytarabine); cytarabine and mitoxantrone
- Enrollment: 326
- Primary outcome: Percentage of Participants With Hematologic Remission (Complete Remission [CR]/Complete Remission With Incomplete Hematologic Recovery [CRi]) as Assessed by the Endpoint Adjudication Committee (EAC)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on INO-VATE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 10
- YouTube: 1
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=ino-vate-nct01564784

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01564784", "email": "<work email>"}; the inbox owner confirms by the emailed link.